<DOC>
	<DOCNO>NCT01440556</DOCNO>
	<brief_summary>Autologous hematopoietic cell transplantation currently consider standard therapy multiple myeloma ( MM ) elegible patient . On contrary , despite new development transplant procedure supportive care , allogeneic bone marrow transplantation less commonly use due high transplant relate mortality ( TRM ) . No consensus statement allografting MM far reach minority patient undergo allografting enrolled prospective clinical trial . Moreover , use unrelated donor considerably increase time recent activity survey European Group Blood Marrow Transplantation ( EBMT ) show number allograft unrelated donor high one HLA-identical sibling Europe . In order evaluate trend allograft unrelated donor multiple myeloma patient , investigator plan conduct restrospective study Italian Bone Marrow Transplantation Registry ( IBMDR ) period range since 2000 2009 . Data collect central data management system Promise ( Project Manager Internet Server ) use EBMT IBMDR . The aim study evaluate role unrelated donor allograft multiple myeloma last decade hopefully offer recommendation patient selection . Primary endpoint study : ) Overall Survival ( OS ) diagnosis allograft b ) Event-Free-Survival ( EFS ) allograft . Disease response criterion define accord International Uniform Response Criteria multiple myeloma . Transplant related mortality , Graft-Versus-Host-Disease ( GVHD ) , either acute chronic ( limited/extensive ) evaluate cumulative incidence . Univariate multivariate analysis calculate transplant-related patient-related characteristic .</brief_summary>
	<brief_title>Allogeneic Bone Marrow Transplantation From Unrelated Donors Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Multiple myeloma patient treat allogeneic bone marrow transplantation unrelated donor ( 2000 2009 : Centri Trapianto GITMO ) No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Allogeneic bone marrow transplantation</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>